The Gene Expression Response of Chronic Lymphocytic Leukemia Cells to IL-4 Is Specific, Depends on ZAP-70 Status and Is Differentially Affected by an NFkB Inhibitor

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Ruiz Lafuente, Natalia ^a,e   Alcaraz García, María José ^a,e   Sebastián Ruiz, Silvia ^a,e   Gómez Espuch, Joaquín ^a,e   Funes, Consuelo ^a,e   Moraleda, José María ^a,c,e   García Garay, María Carmen ^b   Montes Barqueros, Natividad ^a,e   Minguela, Alfredo ^a,d,e   Álvarez López, María Rocío ^a,d,e   Parrado, Antonio ^a,e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO SANTA LUCÍA   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca IMIB Arrixaca   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINO 4 (4 PHENOXYPHENETHYLAMINO)QUINAZOLINE; CD16 ANTIGEN; CD2 ANTIGEN; CD235A ANTIGEN; CD36 ANTIGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG; IL4 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; UPREGULATION; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION PROFILING; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84930679763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109533     Document Type: Article

References (50)

1. Chiorazzi N (2012) Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012: 76-87.
2. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194: 1625-1638.
3. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647.
4. Stratowa C, Löffler G, Lichter P, Stilgenbauer S, Haberl P, et al. (2001) CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 91: 474-480.
5. Zheng Z, Venkatapathy S, Rao G, Harrington CA (2002) Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 16: 2429-2437.
6. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, et al. (2003) Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 1: 346-361.
7. Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV (2004) Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-Analysis of three microarray studies. Bioinformatics 20: 3166-3178.
8. Dürig J, Nückel H, Hüttmann A, Kruse E, Hölter T, et al. (2003) Expression of ribosomal and translation-Associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 101: 2748-2755.
9. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, et al. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951.
10. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, et al. (2004) Microarray analysis reveals that TP53-And ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 103: 291-300.
11. Rodríguez A, Villuendas R, Yáñez L, Gómez ME, Dáz R, et al. (2007) Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 21: 1984-1991.
12. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, et al. (2012) Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 209: 2183-2198.
13. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS (1997) Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of Transforming Growth Factor-b. Blood 89: 941-947.
14. Burger JA, Montserrat E (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of Bcell receptor signaling. Blood 121: 1501-1509.
15. Okada H, Banchereau J, Lotze MT (2003) Interleukin-4. In Thompson AW, Lotze MT, editors. The Cytokine Handbook, Vol. I. London: Academic Press. pp 227-262.
16. Zamorano J, Mora AL, Boothby M, Keegan AD (2001) NF-kappa B activation plays an important role in the IL-4-induced protection from apoptosis. Int Immunol 13: 1479-1487.
17. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164: 2200-2206.
18. CuníS, Pérez-Aciego P, Pérez-Chacón G, Vargas JA, Sánchez A, et al. (2004) A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18: 1391-1400.
19. Thieu VT, Nguyen ET, McCarthy BP, Bruns HA, Kapur R, et al. (2007) IL-4-stimulated NF-kappaB activity is required for Stat6 DNA binding. J Leukoc Biol 82: 370-379.
20. Bhattacharya N, Reichenzeller M, Caudron-Herger M, Haebe S, Brady N, et al. (2014) Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. Int J Cancer. doi: 10.1002/ijc.28974. [Epub ahead of print].
21. Shen CH, Stavnezer J (1998) Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription. Mol Cell Biol 18: 3395-3404.
22. Messner B, Stütz AM, Albrecht B, Peiritsch S, Woisetschläger M (1997) Cooperation of binding sites for STAT6 and NF kappa B/rel in the IL-4-induced up-regulation of the human IgE germline promoter. J Immunol 159: 3330-3337.
23. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, et al. (2011) IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 25: 828-837.
24. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, et al. (1992) Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176: 1319-1326.
25. Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, et al. (2010) The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 116: 4569-4577.
26. Mainou-Fowler T, Proctor SJ, Miller S, Dickinson AM (2001) Expression and production of interleukin 4 in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 42: 689-698.
27. Pangault C, Amé-Thomas P, Ruminy P, Rossille D, Caron G, et al. (2010) Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24: 2080-2089.
28. Schroder AJ, Pavlidis P, Arimura A, Capece D, Rothman PB (2002) Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes. J Immunol 168: 996-1000.
29. Lu X, Nechushtan H, Ding F, Rosado MF, Singal R, et al. (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood 105: 2924-2932.
30. Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Anthoine G, et al. (2010) A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS ONE 5: 12780.
31. Early SB, Barekzi E, Negri J, Hise K, Borish L, et al. (2007) Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells. Am J Respir Cell Mol Biol 36: 715-720.
32. Finkelman FD, Katona IM, Urban JF Jr., Snapper CM, Ohara J, et al. (1986) Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc Natl Acad Sci USA 83: 9675-9678.
33. Kashiwada M, Levy DM, McKeag L, Murray K, Schröder AJ, et al. (2010) IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching. Proc Natl Acad Sci USA 107: 821-826.
34. Alcaraz-García MJ, Ruiz-Lafuente N, Sebastián-Ruiz S, Majado MJ, González-García C, et al. (2011) Human and mouse DOCK10 splicing isoforms with alternative first coding exon usage are differentially expressed in T and B lymphocytes. Hum Immunol 72: 531-537.
35. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, et al. (2003) A novel structural class of potent inhibitors of NF-kappa B activation: structure-Activity relationships and biological effects of 6-Aminoquinazoline derivatives. Bioorg Med Chem 11: 3869-3878.
36. Kaminski A, Demaine A, Prentice A (1998) Cytoplasmic interleukin-4 (IL-4) and surface IL-4 receptor expression in patients with B-cell lymphocytic leukemia. Blood 92: 2188-2189.
37. Moskalev EA, Luckert K, Vorobjev IA, Mastitsky SE, Gladkikh AA, et al. (2012) Concurrent epigenetic silencing of wnt/b-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia. BMC Cancer 2012; 12: 213.
38. Lafarge ST, Johnston JB, Gibson SB, Marshall AJ (2014) Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway. Leuk Res 38: 109-115.
39. Willimott S, Baou M, Naresh K, Wagner SD (2007) CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 138: 721-732.
40. Cosimo E, McCaig AM, Carter-Brzezinski LJM, Wheadon H, Leach MT, et al. (2013) Inhibition of NF-kB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells. Clin Cancer Res 19: 2393-2405.
41. Rong R, Ahn JY, Huang H, Nagata E, Kalman D, et al. (2003) PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 6: 1153-1161.
42. Huang GN, Huso DL, Bouyain S, Tu J, McCorkell KA, et al. (2008) NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 319: 476-481.
43. Jantus Lewintre E, Reinoso Martín C, García Ballesteros C, Pendas J, Benet Campos C, et al. (2009) BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia. Leuk Lymphoma 50: 773-780.
44. López-Guerra M, RouéG, Pérez-Galán P, Alonso R, Villamor N, et al. (2009) p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res 15: 2767-2776.
45. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, et al. (2008) ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111: 2685-2692.
46. Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, et al. (2011) ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 118: 4401-4410.
47. Pickering BM, de Mel S, Lee M, Howell M, Habens F, et al. (2007) Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26: 1166-1177.
48. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, et al. (2008) The NFkappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111: 4681-4689.
49. Burgess M, Cheung C, Chambers L, Ravindranath K, Minhas G, et al. (2012) CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leuk Lymphoma 53: 1988-1998.
50. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, et al. (1997) Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci U S A 94: 2609-2614.